MICHAEL MCGARRITY
CEO
MDXHEALTH SA
WHY: Heads a restructured diagnostics company that’s become one-stop shop for noninvasive prostate tests. Arrived as CEO in 2019 when the company had one product and about $11.8M in annual sales. This year, the company is projecting between $108M and $110M for full-year revenue.
IN THE NEWS: Achieved first quarter of operating profitability during the fourth quarter of this year. Also announced acquisition of Exosome Diagnostics business from Minneapolis-based Bio-Techne Ltd. for $15M, adding a new liquid biopsy test to its portfolio.
NOTABLE: Has seen quarterly revenue growth of 20% or more for 17 consecutive quarters. Shares doubled in past year; now has $247M market cap.
QUOTABLE: “We’ve done it by expanding our menu through both acquisitions and what I call channel growth opportunities.”
